Mark A Lewis1, Fengmin Zhao2, Desiree Jones3, Charles L Loprinzi4, Joanna Brell5, Matthias Weiss6, Michael J Fisch1. 1. Department of General Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 2. Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA. 3. Department of General Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Electronic address: djones1@mdanderson.org. 4. Breast and Oncology Departments, Mayo Clinic, Rochester, Minnesota, USA. 5. National Cancer Institute, Rockville, Maryland, USA. 6. Marshfield Clinic, Marshfield, Wisconsin, USA.
Abstract
CONTEXT: Few studies have examined the prevalence and severity of treatment-induced neuropathic symptoms in patients across different cancer types. OBJECTIVES: This study aimed to report the prevalence of numbness/tingling (N/T) and neuropathic pain in patients with colorectal cancer (CRC) vs. other cancers, describe the prevalence of moderate-to-severe N/T by specific clinical variables, and examine factors associated with the presence of these symptoms. METHODS: A total of 3106 outpatients with colorectal (n = 718), breast (n = 1544), lung (n = 524), or prostate (n = 320) cancer were enrolled at any point in their treatment. Assessments were conducted at the initial visit and 28-35 days later. Patients reported pain and N/T; clinicians reported mechanism of pain and ranked the top three symptoms causing difficulties. RESULTS: Moderate-to-severe N/T was higher in patients with CRC relative to other cancer types (25.8% vs. 17.1%, P < 0.001); 25% vs. 10.5% of clinicians rated N/T as a top three symptom for patients with CRC relative to other cancers (P < 0.001). The prevalence of neuropathic pain was comparable between patients with CRC and other cancers (P = 0.654). Patients with CRC, longer duration of cancer, prior therapy, on current therapy, older patients, and patients of black race experienced worse N/T. CONCLUSION: Patients with CRC experience significantly higher rates of N/T but comparable neuropathic pain, relative to patients with other cancers. Awareness of the prevalence and severity of neuropathic symptoms and their associated risk factors in this patient population is critical for both clinicians and patients.
CONTEXT: Few studies have examined the prevalence and severity of treatment-induced neuropathic symptoms in patients across different cancer types. OBJECTIVES: This study aimed to report the prevalence of numbness/tingling (N/T) and neuropathic pain in patients with colorectal cancer (CRC) vs. other cancers, describe the prevalence of moderate-to-severe N/T by specific clinical variables, and examine factors associated with the presence of these symptoms. METHODS: A total of 3106 outpatients with colorectal (n = 718), breast (n = 1544), lung (n = 524), or prostate (n = 320) cancer were enrolled at any point in their treatment. Assessments were conducted at the initial visit and 28-35 days later. Patients reported pain and N/T; clinicians reported mechanism of pain and ranked the top three symptoms causing difficulties. RESULTS: Moderate-to-severe N/T was higher in patients with CRC relative to other cancer types (25.8% vs. 17.1%, P < 0.001); 25% vs. 10.5% of clinicians rated N/T as a top three symptom for patients with CRC relative to other cancers (P < 0.001). The prevalence of neuropathic pain was comparable between patients with CRC and other cancers (P = 0.654). Patients with CRC, longer duration of cancer, prior therapy, on current therapy, older patients, and patients of black race experienced worse N/T. CONCLUSION:Patients with CRC experience significantly higher rates of N/T but comparable neuropathic pain, relative to patients with other cancers. Awareness of the prevalence and severity of neuropathic symptoms and their associated risk factors in this patient population is critical for both clinicians and patients.
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Sherry L Wolf; Debra L Barton; Rui Qin; Edward J Wos; Jeff A Sloan; Heshan Liu; Neil K Aaronson; Daniel V Satele; Bassam I Mattar; Nathan B Green; Charles L Loprinzi Journal: Support Care Cancer Date: 2011-04-12 Impact factor: 3.603
Authors: Rebecca M Speck; Mary D Sammel; John T Farrar; Sean Hennessy; Jun J Mao; Margaret G Stineman; Angela DeMichele Journal: J Oncol Pract Date: 2013-04-30 Impact factor: 3.840
Authors: Bruno Vincenzi; Anna Maria Frezza; Gaia Schiavon; Chiara Spoto; Nicola Silvestris; Raffaele Addeo; Vincenzo Catalano; Francesco Graziano; Daniele Santini; Giuseppe Tonini Journal: Support Care Cancer Date: 2012-11-30 Impact factor: 3.603
Authors: Desiree Jones; Fengmin Zhao; Joanna Brell; Mark A Lewis; Charles L Loprinzi; Matthias Weiss; Michael J Fisch Journal: J Cancer Surviv Date: 2014-07-15 Impact factor: 4.442
Authors: Xin Shelley Wang; Qiuling Shi; Patrick M Dougherty; Cathy Eng; Tito R Mendoza; Loretta A Williams; David R Fogelman; Charles S Cleeland Journal: Oncology Date: 2016-02-17 Impact factor: 2.935
Authors: Judith A Paice; Matt Mulvey; Michael Bennett; Patrick M Dougherty; John T Farrar; Patrick W Mantyh; Christine Miaskowski; Brian Schmidt; Thomas J Smith Journal: J Pain Date: 2016-11-21 Impact factor: 5.820
Authors: Suvarna Gadgil; Mehmet Ergün; Sandra A van den Heuvel; Selina E van der Wal; Gert Jan Scheffer; Carlijn R Hooijmans Journal: PLoS One Date: 2019-08-28 Impact factor: 3.240
Authors: Alex Molassiotis; Hui Lin Cheng; Kwun To Leung; Yu Chung Li; Kam Hung Wong; Joseph Siu Kie Au; Raghav Sundar; Alexandre Chan; Terrence Rong De Ng; Lorna K P Suen; Choi Wan Chan; Janelle Yorke; Violeta Lopez Journal: Brain Behav Date: 2019-05-07 Impact factor: 2.708